Received Oct 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | J9493 | — |
HCP administered AREXVY to a pregnant patient; HCP administered AREXVY to a pregnant patient; Inappropriate age at vaccine administration; This non-serious prospective pregnancy case was reported by a pharmacist via call center representative and described the occurrence of vaccine exposure during pregnancy in a adult female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number J9493, expiry date 01-NOV-2025) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced vaccine exposure during pregnancy (Verbatim: HCP administered AREXVY to a pregnant patient), product use in unapproved population (Verbatim: HCP administered AREXVY to a pregnant patient) and inappropriate age at vaccine administration (Verbatim: Inappropriate age at vaccine administration). The outcome of the vaccine exposure during pregnancy, product use in unapproved population and inappropriate age at vaccine administration were not applicable. Pregnancy exposure: Gestation time at first exposure (Arexvy): 32 Weeks Pregnancy Exposure (Arexvy): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date: 27-OCT-2025 Pharmacist reported another healthcare professional administered Arexvy to a pregnant patient. Pharmacist didn't have delivery date but states patient is 32 weeks pregnant.